4D Molecular Therapeutics
Clinical trials sponsored by 4D Molecular Therapeutics, explained in plain language.
A biotech developing gene therapies using AAV vectors.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Time gene shot could cut eye injections for wet AMD Results expected Mar 2027 (estimated)
- One shot to save sight? gene therapy aims to cut eye injections for wet AMD Results expected Jun 2027 (estimated) 🚀 Make-or-break
- Inhaled gene therapy aims to fix cystic fibrosis lungs Results expected Jun 2027 (estimated)
-
Gene therapy shot aims to cut eye injections for diabetic vision loss
Disease control OngoingThis phase 2 trial tests a gene therapy called 4D-150 for diabetic macular edema, a condition that causes vision loss in people with diabetes. The study involves 72 adults who will receive either the gene therapy or standard aflibercept injections. The goal is to see if a single …
Phase 2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
One shot to save sight? gene therapy aims to cut eye injections for wet AMD
Disease control OngoingThis phase 3 trial tests a single injection of 4D-150 gene therapy in 480 adults with wet age-related macular degeneration (AMD). The goal is to see if one treatment can control the disease as well as or better than standard aflibercept injections given every few weeks. Participa…
Phase 3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC